12 results about "Drospirenone" patented technology

The present invention relates to a composition comprising an estetrol component and drospirenone for use in treating unscheduled bleeding and spotting in an adolescent female subject. The invention also encompasses associated uses and methods of contraception as well as improving health-related quality of life and alleviating menstrual symptoms in adolescent subjects.

This invention relates to methods for treating endometriosis and providing effective contraception. Specifically, it relates to drospirenone in methods for treating endometriosis, endometriosis-associated pelvic pain (EAPP), and / or dysmenorrhea, the method comprising administering drospirenone in a biphasic regimen. The invention also relates to the use of drospirenone administered in such a biphasic regimen as a contraceptive and for inducing amenorrhea, and to pharmaceutical compositions and devices comprising drospirenone administered in such a biphasic regimen.

This invention discloses the application of ethinylestradiol and drospirenone in the preparation of drugs for treating post-traumatic stress disorder (PTSD). Ethinylestradiol, as an estrogen receptor agonist, regulates the hypothalamic-pituitary-gonadal axis and is used to treat female hypogonadism, menopausal syndrome, and advanced breast cancer, often in combination with progestins as oral contraceptives. The use of drospirenone and ethinylestradiol tablets (II) after induced abortion can shorten vaginal bleeding time, promote endometrial repair, and reduce the incidence of postoperative complications and repeat miscarriages. This invention has found that ethinylestradiol and drospirenone can reverse the abnormal decrease in hormones and neurosteroids caused by PTSD after spontaneous abortion, particularly the abnormal decrease in serotonin and tetrahydroprogesterone.

The present invention relates to a pharmaceutical composition comprising estetrol and drospirenone for use in relieving pain associated with endometriosis in a patient. The pharmaceutical compositions described in the present invention are particularly effective in relieving pain associated with endometriosis in patients having high levels, frequencies and / or intensities of pain, e.g., measured by visual analog scale (VAS) scoring, and / or with other complications such as adenomyosis or hysteromyoma. Uses related to the above and corresponding methods of treatment are also described.

Use of drospirenone in an amount of at least 3 mg contained in a daily active dosage unit as the sole contraceptive ingredient as a contraceptive for obese female patients.

The present invention relates to drospirenone for use in a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and / or dysmenorrhea, comprising administering drospirenone in a biphasic regimen. The present invention furthermore relates to the use of drospirenone administered in such a biphasic regimen as a contraceptive and for inducing amenorrhea, as well as to a pharmaceutical composition and a kit comprising drospirenone administered in such a biphasic regimen.

The present invention refers to a process for the industrial-scale preparation of 17β-hydroxy-6β,7β; 15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone, known by the common name of Drospirenone, in the form of a fine powder without the use of mechanical grinding or micronization techniques, but rather exploiting a double change of crystalline form, from Crystalline Form I to Crystalline Form II and from Crystalline Form II to Crystalline Form I. The invention also refers to the new Crystalline Form II of Drospirenone obtained in the process.

The present application relates to the field of pharmaceutical analysis method, specifically relates to a kind of detection method of related substance in drospirenone ethinylestradiol tablet (II).The method can simultaneously determine drospirenone ethinylestradiol tablet (II) drospirenone, ethinylestradiol and 13 kinds of related substances, method specificity is strong, sensitivity is high, suitable for drospirenone ethinylestradiol tablet (II) Process research, intermediate process control, finished product quality detection and stability research.

The invention provides application of blood nourishing oral liquid combined with drospirenone ethinylestradiol in clinical symptoms and endometrial receptivity after an induced abortion operation, and belongs to the technical field of biological medicine. According to the application of the blood nourishing oral liquid and the drospirenone ethinylestradiol in preparation of the medicine for improving the clinical symptoms after the induced abortion operation, the result of the embodiment shows that compared with a drospirenone ethinylestradiol single administration group, the combined administration group has the advantages that the vaginal bleeding duration is shorter, the vaginal bleeding amount is smaller, the abdominal pain degree is lower, and the clinical symptoms after the induced abortion operation can be improved. The dominant follicle size, the endometrial thickness, the endometrial volume, the type A endometrial rate, the type III endometrial and the ratio of the endometrial-muscular layer binding band are all higher than those of a control group, and the aneurysm hemodynamic indexes are all lower than those of a single administration group. Therefore, the blood-nourishing oral liquid combined with drospirenone ethinylestradiol can effectively improve postoperative clinical symptoms of patients, promote follicle development and improve endometrial receptivity.

The present invention relates to drospirenone for use in a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and / or dysmenorrhea, comprising administering drospirenone in a biphasic regimen. The present invention furthermore relates to the use of drospirenone administered in such a biphasic regimen as a contraceptive and for inducing amenorrhea, as well as to a pharmaceutical composition and a kit comprising drospirenone administered in such a biphasic regimen.

The invention relates to the technical field of synthesis, and discloses a synthesis method of a drospirenone EP impurity E. The method comprises the following steps: adding a compound I, vinylboronic acid pinacol ester, stannic chloride and chiral diol into a first organic solvent, reacting for a first time at a first temperature, extracting, drying, and carrying out column chromatography separation to obtain a compound II; dissolving the compound II in a second organic solvent, adding acetic anhydride, a palladium catalyst and a catalyst ligand, replacing and introducing carbon dioxide, stirring and reacting for a second time at a second temperature, and performing extraction, drying and column chromatography separation to obtain a compound III; and dissolving the compound III in a third organic solvent, adding a condensing agent, carrying out a stirring reaction at a third temperature for a fourth period of time, and carrying out extraction, drying and column chromatography separation to obtain the compound 17R-Drospirenone. In the embodiment of the invention, the synthesis route of the drospirenone EP impurity E is short, the yield is high, and the synthesis cost of the drospirenone EP impurity E is effectively reduced.

The present invention relates to drospirenone for use in a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and / or dysmenorrhea, comprising administering drospirenone in a biphasic regimen. The present invention furthermore relates to the use of drospirenone administered in such a biphasic regimen as a contraceptive and for inducing amenorrhea, as well as to a pharmaceutical composition and a kit comprising drospirenone administered in such a biphasic regimen.